Holen Sie sich die Stockscreener-App
14.28
3.32%
-0.49
Handel nachbörslich:
14.25
-0.03
-0.21%
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - TradingView
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - TradingView
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock - Investing.com
GSA Capital Partners LLP Acquires Shares of 115,535 NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake - Stock Titan
H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Q2 revenue up 21% to USD 22.8M - Medical Buyer
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroPace (NASDAQ:NPCE) Shares Gap DownHere's Why - MarketBeat
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up - sg.finance.yahoo.com
NeuroPace, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Neuropace earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Technical Reactions to NPCE Trends in Macro Strategies - Stock Traders Daily
NeuroPace Inc.: Q2 Earnings Snapshot - aol.com
NeuroPace Q2 Earnings Call Highlights - MarketBeat
NeuroPace Raises FY26 Sales Guidance Above Estimates - scanx.trade
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance - Investing News Network
NPCE: Q2 revenue up 17% to $22.8M; guidance raised; IGE FDA review ongoing with positive outlook - TradingView
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
NPCE: Revenue up 17% with strong RNS growth; guidance raised; IGE approval path remains active - TradingView
Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours - Investing.com
NeuroPace Q2 EPS beats estimates as revenue rises 17% to $22.8 million - scanx.trade
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
NeuroPace, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
NeuroPace Inc 2Q 2026: Revenue $22.8M, Net loss $(6.2M), EPS $(0.18) — 10-Q Summary - TradingView
NeuroPace, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NeuroPace, Inc. Revises Earnings Guidance for the Full Year of 2026 - marketscreener.com
NeuroPace Q2 2026 slides: 21% RNS growth, $55B+ market opportunity - Investing.com Canada
Neuropace Inc (NASDAQ: NPCE) Share Price, NPCE Stock News, NPCE Share Price & Updates - Kalkine
Enterprise value to EBIT forward of Neuropace, Inc. – NASDAQ:NPCE - TradingView
NeuroPace, Inc. expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Neuropace Inc (NPCE) Stock News Today - TradingKey
Neuropace, Inc. (NPCE) Stock Analysis: A 45% Potential Upside Awaits Investors - DirectorsTalk Interviews
Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11 - Moomoo
NeuroPace (NPCE) Expected to Release Earnings on Tuesday - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Trading the Move, Not the Narrative: (NPCE) Edition - Stock Traders Daily
Neuropace, Inc. Revenue Breakdown – NASDAQ:NPCE - TradingView
Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cantor Fitzgerald Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $21 - Moomoo
HC Wainwright Reaffirms Buy Rating for NeuroPace (NASDAQ:NPCE) - marketbeat.com
H.C. Wainwright reiterates Buy on NeuroPace stock after FDA feedback By Investing.com - Investing.com Nigeria
NeuroPace (NASDAQ:NPCE) Draws Attention After Fresh Market Update - Kalkine Media
NeuroPace stock tumbles as FDA declines epilepsy expansion By Investing.com - Investing.com Australia
NeuroPace’s epilepsy device expansion hits FDA roadblock By Investing.com - Investing.com Nigeria
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy - Business Wire
NeuroPace to submit SIR after FDA rejects IGE indication supplement - scanx.trade
Neuropace Inc (NPCE) Cash Flow - TradingKey
Orbimed Advisors LLC Decreases Holdings in NeuroPace, Inc. $NPCE - MarketBeat
Neuropace Inc (NPCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NeuroPace, Inc. $NPCE Shares Acquired by First Light Asset Management LLC - MarketBeat
NPCE|Neuropace Inc|Price:14.810|Chg%:+0.130 - TradingKey
Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuropace Inc (NPCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuropace Inc (NPCE) Balance Sheet - TradingKey
Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis - TradingKey
NeuroPace Inc introduces real-time solution to help restore everyday independence - Traders Union
NPCE|Neuropace Inc|Price:13.876|Chg%:+0.376 - TradingKey
Neuropace Inc (NPCE) Income Statement - TradingKey
NeuroPace Inc: Intermountain Health completes 100th RNS System implant for epilepsy patients - Traders Union
Neuropace Inc (NPCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mizuho Securities Initiates NeuroPace(NPCE.US) With Buy Rating, Announces Target Price $22 - Moomoo
Mizuho Begins Coverage on NeuroPace (NASDAQ:NPCE) - MarketBeat
NEUROPACE INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $22 - Bitget
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):